bivalirudin · Maia Pharms Inc · NDA 211215
Angiomax Rtu
Earliest generic entry, as listed
20 May 2039
Blocked by patent: US 11903993, US 11918622, US 11992514, US 12472224.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11903993 | use U-3817 | 20 May 2039 |
| US 11918622 | use U-3817 | 20 May 2039 |
| US 11992514 | product | 20 May 2039 |
| US 12472224 | product, use U-3817 | 20 May 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211215 · 001 · RLD | solution, intravenous | 250MG/50ML (5MG/ML) | 20 May 2039 |